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CTLA-4 (CD152) shares its ligand with a costimula-
tory molecule, CD28, and functions as a negative
regulator in T cell activation. We examined the role
of CTLA-4 in both induction and effector phases of
contact hypersensitivity induced by using two aller-
gens. Treatment with anti-CTLA-4 monoclonal
antibody at sensitization, but not at challenge, sig-
ni®cantly enhanced Th1- and Th2-dominant contact
hypersensitivity reactions elicited by dinitro¯uoro-
benzene and ¯uorescein isothiocyanate, respectively.
CTLA-4 was faintly expressed on regional lymph
node T cells even in naõÈve mice, and its transcription
determined by reverse transcriptase polymerase
chain reaction was clearly enhanced at 72 h after sen-
sitization. Treatment with anti-CTLA-4 monoclonal
antibody at sensitization signi®cantly augmented the
total cell number in regional lymph nodes and pro-
liferative responses of T cells against speci®c haptens.
This higher sensitivity in lymph node T cells against
speci®c haptens was maintained over the month after
treatment. Our results suggest that CTLA-4 on T
cells may regulate the induction of antigen-speci®c T
cells in the regional lymph nodes in allergic contact
dermatitis. Key words: contact hypersensitivity/CTLA-4/
regional lymph nodes/T cell regulation. J Invest Dermatol
116:764±768, 2001
C
ytotoxic T-lymphocyte-associated Ag-4 (CTLA-4,
CD152) is a homolog of CD28; it is expressed on the
surface of activated T lymphocytes and shares its
ligands, CD80 and CD86, with CD28. CTLA-4 is
hardly detectable on resting T cells, transiently
induced only after activation, and its surface expression is restricted
by clathrin-mediated endocytosis (Shiratori et al, 1997). Despite
low surface expression, CTLA-4 has a much higher avidity for
CD80 and CD86 than CD28 (Linsley et al, 1991; Lanier et al,
1995). CTLA-4 functions as a negative regulator in T cell
activation (Walunas et al, 1994; Kearney et al, 1995; Krummel
and Allison, 1995; Perrin et al, 1996) and may play a critical role in
the induction and maintenance of peripheral tolerance (Chambers
et al, 1996; Perez et al, 1997). Blockade of CTLA-4 accelerated a
number of T-cell-mediated immune responses against allo-Ag
(Judge et al, 1999; Zheng et al, 1999), auto-Ag (Chambers et al,
1996; Perez et al, 1997), and nematode-Ags (McCoy et al, 1997).
Contact hypersensitivity (CH) has served as a useful model for
investigating the allergen-speci®c immune responses of T cells and
skin-associated antigen-presenting cells. Previously, we (Nuriya
et al, 1996) and colleagues (Reiser and Schneeberger, 1996) have
demonstrated a critical role of CD28 costimulation through
preferential interaction with CD86 on Langerhans cells in the
induction phase of hapten-induced CH. In this study, we
investigated the role of CTLA-4 in CH reactions by examining
the effect of CTLA-4 blockade by in vivo administration of anti-
CTLA-4 monoclonal antibody (MoAb) on CH reactions induced
by two different allergens, dinitro¯uorobenzene (DNFB) and
¯uorescein isothiocyanate (FITC). We further investigated T cell
function in the regional lymph nodes (LN) after the anti-CTLA-4
MoAb treatment.
MATERIALS AND METHODS
Mice Female BALB/C mice were obtained from Japan SLC
(Hamamatsu, Shizuoka, Japan), maintained under speci®c pathogen-free
conditions, and used at 7±8 wk of age. All mice procedures were
reviewed and approved by the Animal Care and Use Committee in the
National Children's Medical Research Center.
Monoclonal antibodies and ¯ow cytometry A hybridoma, UC10±
4F10.11 (anti-CTLA-4, hamster IgG), was kindly provided by Dr. J. A.
Bluestone (University of Chicago). The MoAb was puri®ed from ascites
by standard procedures using caprylic acid extraction, and its purity was
veri®ed by sodium dodecyl sulfate polyacrylamide gel electrophoresis.
For ¯ow cytometric analysis, MoAbs against CTLA-4 (4F10, hamster
IgG), CD69 (H1.2F3, hamster IgG), and CD25 (7D4, rat IgM) were
used. All ¯uorochrome-conjugated MoAbs and control Igs were
obtained from PharMingen (San Diego, CA). Immuno¯uorescence and
¯ow cytometry were performed by using FACSort and CellQuest
software (Becton Dickinson Immunocytometry Systems, San Jose, CA).
Induction of CH and MoAb treatment CH to DNFB (Sigma, St.
Louis, MO) and FITC (¯uorescein isothiocyanate isomer-I, Dojindo,
Kumamoto, Japan) was induced as previously described (Nuriya et al,
1996; Tang et al, 1996). Brie¯y, for FITC sensitization, 400 ml of 0.5%
FITC dissolved in acetone:dibutylpthalate (1:1) was painted on shaved
abdominal skin on day 0. Six days later (day 6), mice were challenged by
applying 20 ml of 0.5% FITC onto both surfaces of the ear. For DNFB-
induced CH reactions, 20 ml of 0.5% DNFB dissolved in acetone:olive
oil (4:1) was painted on days 0 and 1, and then mice were challenged
with 10 ml of 0.2% DNFB on day 5. The ear thickness was measured
before and 24 h after challenge as described previously (Nuriya et al,
1996). For MoAb treatment, groups of four to six mice received
intraperitoneal injection with 250 mg per mouse of anti-CTLA-4 MoAb
or control hamster IgG (PharMingen) in a total volume of 0.5 ml 2 h
prior to every sensitization or challenge. The ear thicknesses of mice that
were painted with the vehicle control alone and challenged are presented
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as negative controls. In the experiment to determine the speci®city of
CH in vivo, all groups of mice were primary sensitized with FITC after
treatment with control Ig or anti-CTLA-4 MoAb. On day 35 and/or
36, mice were resensitized with secondary hapten, either DNFB or
FITC, and then challenged with the same hapten as the secondary
sensitizatiion on day 40.
Isolation of regional LN cells LN cells were collected from draining
regional (inguinal, brachial, and axillary) lymph nodes from intact mice
and the mice were treated with either control Ig or anti-CTLA-4 MoAb
at the indicated time points after primary sensitization or challenge.
Single cell suspensions of LN cells were used for ¯ow cytometric analysis
and proliferation assay. For T cell puri®cation, LN cells were treated
with anti-I-A and anti-CD24 MoAb and rabbit complement as described
previously (Nuriya et al, 1996).
Reverse transcriptase polymerase chain reaction (RT-PCR) for
CTLA-4 Total RNA was extracted from LN cells by using the Trizol
reagent (Gibco-BRL, Rockville, MD). First-strand cDNA was synthe-
sized using oligo(dT) primer and Superscript II reverse transcriptase
(Gibco BRL). PCR was performed using mouse CTLA-4 primers
(sense, TCAGTTGATGGCAATAAAATA; antisense, ATGGCTTGT-
CTTGGACTCCGG) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) primers (sense, CCATCACCATCTTCCAGGAG; antisense,
CTTGCTTCACCACCTTCTTG). Serially diluted cDNA samples were
ampli®ed on a DNA thermal cycler (Perkin Elmer) for 40 cycles (94°C
for 1 min, 55°C for 1 min, and 72°C for 2 min) followed by a 15 min
extension at 72°C. The PCR products were electrophoresed on 1%
agarose gel. The gel was stained with ethidium bromide and
photographed under ultraviolet light. The sizes of ampli®ed products for
CTLA-4 and GAPDH were 674 and 576 bp, respectively.
Hapten-speci®c T cell proliferation assay To examine spontaneous
proliferation of LN cells, LN cells (2 3 105 per well) at 24 h after
challenge were cultured in complete RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mg per ml
gentacine, and 50 mM 2-mercaptoethanol in 96-well ¯at-bottom plates
for 3 d. For in vitro hapten pulse, the LN cells obtained were incubated
with 10 mM 2,4-dinitrobenzene-sulfonic acid (DNBS, a water-soluble
analog of DNFB; Tokyo Kasei, Tokyo, Japan) for 10 min at 37°C. The
doses of hapten that gave optimal stimulation but were not toxic to LN
cells were determined in preliminary experiments. After extensive
washing, cells (4 3 105 per well) were cultured for 3 d in complete
medium. All cultures were pulsed with 1 mCi per well 3H-thymidine
(DuPont-NEN, Boston, MA) for the ®nal 18 h, harvested, and measured
for incorporated radioactivity using a cell harvester and counting system
(INB384 and Trace 96, Inotech, Lansing, MI).
Statistical analysis Signi®cant differences between experimental
groups were analyzed using Student's t test.
RESULTS
Treatment with anti-CTLA-4 MoAb in the induction phase,
but not effector phase, enhances CH responses induced by
DNFB and FITC It has been shown that CH to DNFB
induced a Th1-type immune response in BALB/C mice, whereas
CH to FITC induced a Th2-type immune response based on the
results of the ratio of interleukin-4- to interferon-g-secreting cells
in draining LN (Tang et al, 1996). To investigate the functional
contribution of CTLA-4 in the CH reaction, we examined the
effects of anti-CTLA-4 MoAb treatment at sensitization and
challenge using Th1- and Th2-dominant CH models. In the Th1-
dominant CH model induced by DNFB, the treatment with anti-
CTLA-4 MoAb at sensitization signi®cantly enhanced the ear
swelling compared with control Ig-treated mice, whereas the
treatment at challenge did not signi®cantly affect ear swelling
(Fig 1A). Similar results were observed by using antigen-binding
fragment of anti-CTLA-4 MoAb (not shown), suggesting a
blocking effect of anti-CTLA-4 MoAb. The effect of treatment
with anti-CTLA-4 MoAb was also con®rmed by histologic
examination. The ear in the anti-CTLA-4-treated mice in the
induction phase showed much severe swelling, edema, and
leukocyte in®ltration, in comparison to control Ig-treated mice
(not shown). Similar results were observed in the Th2-dominant
CH model induced by FITC (Fig 1B). The treatment with anti-
CTLA-4 MoAb in the induction phase signi®cantly enhanced CH
reaction, although the level of ear swelling in the FITC-induced
CH was consistently lower than that observed in the DNFB-
induced CH. These results demonstrated that treatment with anti-
CTLA-4 MoAb in the induction phase enhanced both Th1- and
Th2-mediated CH reactions.
Activation of LN T cells by anti-CTLA-4 MoAb treat-
ment To investigate T cell state after anti-CTLA-4 treatment at
sensitization, we next examined the cell number and activation
markers, CD25 and CD69, in the regional LN. Draining LN from
unsensitized mice or DNFB-sensitized mice treated with control Ig
or anti-CTLA-4 MoAb were removed 3 d after the ®nal
sensitization. The total cell number in the LN was signi®cantly
increased by sensitization and further enhanced by the treatment
with anti-CTLA-4 MoAb (Fig 2A). The administration of anti-
CTLA-4 MoAb without sensitization slightly increased the number
of LN cells, although it was not signi®cant. Treatment with anti-
CTLA-4 MoAb did not alter the ratio of CD3+ T cells in LN cells
(not shown). As shown in Fig 2(B), a small fraction of T cells
expressed CD69 and CD25 without sensitization and DNFB
sensitization slightly increased the percentage of CD69+ T cells, but
not CD25+ T cells. Administration of anti-CTLA-4 MoAb at
sensitization augmented the induction of both CD25 and CD69.
These observations suggested that the treatment with anti-CTLA-4
MoAb at sensitization enhanced the number of lymphocytes in
draining LN and T cell activation.
Expression of CTLA-4 on T cells in the draining LN To
determine the actual in situ expression of CTLA-4, we examined
cell surface expression of CTLA-4 on T cells in the regional
draining LN by ¯ow cytometry. A small population of CD3+ T
cells express CTLA-4 in the naõÈve mice. The expression level was
slightly increased at 72 h after sensitization, although a clear
difference was not observed. Similar results were observed in the
cytoplasmic staining for intracellular CTLA-4 (not shown). As cell
surface expression of CTLA-4 is restrictedly regulated by both
transcriptional and post-transcriptional levels (Shiratori et al, 1997;
Zhang and Allison, 1997; Oki et al, 1999), we next examined
CTLA-4 transcriptions by semiquantitative RT-PCR. The
CTLA-4 mRNA was minimally detectable in unsensitized mice,
was kept at a similar level until 6 h after sensitization, and was then
enhanced and clearly augmented at 72 h (Fig 3B). The hapten
Figure 1. Administration of anti-CTLA-4 MoAb in the induction
phase enhances CH reactions. CH against DNFB (A) and FITC (B)
was induced as described in Materials and Methods. Anti-CTLA-4 MoAb
was injected intraperitoneally 2 h before every sensitization or challenge.
The ear thickness was evaluated before and 24 h after challenge. These
data represent a summary of ®ve experiments with three to four mice
per group. Values are the mean thickness change 6 SD. Statistically
different (*p < 0.05).
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challenge did not further enhance expression for CTLA-4 mRNA
(not shown). These results demonstrated that a small amount of
CTLA-4 is constitutively expressed on T cells even in naive mice
and CTLA-4 transcriptions were enhanced by sensitization.
Treatment with anti-CTLA-4 MoAb induces Ag-speci®c T
cell activation In the LN cells from DNFB-challenged mice,
spontaneous proliferative responses were observed (Fig 4A). LN
cells from the sensitized mice proliferated ef®ciently compared with
unsensitized mice and this was signi®cantly augmented by the anti-
CTLA-4 treatment at sensitization. To investigate whether the
augmented T cell proliferative responses are hapten-speci®c, we
examined in vitro proliferation of LN cells to Ag after anti-CTLA-4
MoAb treatment. LN cells obtained from sensitized or unsensitized
mice were pulsed with DNBS and cultured for 3 d (Fig 4B). LN
cells from DNFB-sensitized mice treated with anti-CTLA-4 MoAb
showed a signi®cantly high spontaneous proliferative response, and
this was further enhanced by the in vitro hapten pulse. LN cells from
unsensitized mice treated with anti-CTLA-4 MoAb showed a low
but signi®cantly higher proliferative response compared with the
controI Ig-treated mice. These results indicated that administration
of anti-CTLA-4 MoAb at primary Ag sensitization clearly
augmented the T cell proliferative responses against secondary
stimulation both in vivo and in vitro. An applied-hapten-
independent T cell activation was also induced by the anti-
CTLA-4 treatment.
Figure 3. CTLA-4 expression after sensitization. Draining LN at
the indicated time after DNFB sensitization were removed and cell
surface expression (A) and mRNA expression (B) for CTLA-4 was
measured. (A) LN cells were stained with FITC-anti-CD3 and PE-anti-
CTLA-4 MoAbs, or with appropriate ¯uorochrome-conjugated control
Ig, and samples were analyzed by ¯ow cytometry. Representative data
from three individuals are displayed as dot plots (four-decade log scale).
The mean percentages 6 SD for CTLA-4+ cells in LN cells are
indicated. (B) Total RNA from LN cells was isolated, and a series of 3-
fold diluted cDNA samples were subjected to PCR for CTLA-4 and
GAPDH.
Figure 4. Proliferative responses of LN cells after the anti-CTLA-4
MoAb treatment at sensitization. (A) Spontaneous proliferation in LN
cells after challenge. Unsensitized and DNFB-sensitized mice treated with
or without anti-CTLA-4 MoAb were challenged with DNFB. Lymph
nodes were removed 24 h after challenge and LN cells (4 3 105 per well)
were cultured in complete medium for 3 d. (B) Proliferative responses of
LN cells against DNBS. Lymph nodes were removed at 72 h after the
®nal sensitization. DNBS-pulsed or unpulsed LN cells from each group of
mice were cultured for 3 d as described above. All cultures were pulsed
with 3H-thymidine for the ®nal 16 h and incorporated radioactivity was
measured. Each bar shows the mean 6 SEM of triplicate wells. Data are
representative of three experiments with similar results. Statistically
different (*p < 0.05, **p < 0.01).
Figure 2. Treatment with anti-CTLA-4 MoAb increases total cell
number of LN and activation antigens on T cells. (A) LN at 72 h
after ®nal sensitization were removed and total cell number was counted.
Values represent the mean 6 SD from each group with four mice.
Statistically different (*p < 0.05). (B) LN cells from unsensitized mice,
DNFB-sensitized mice treated with control Ig or anti-CTLA-4 MoAb at
72 h after sensitization were stained with PE-anti-CD3 and FITC-anti-
CD69 MoAbs, FITC-anti-CD3 and biotinylated anti-CD25 MoAbs, or
with appropriate ¯uorochrome-conjugated control Ig. For staining with
biotinylated MoAb, PE-streptavidin was used for visualization. Samples
were analyzed by ¯ow cytometry. An electronic gate was set on CD3+
lymphocytes; differential expression for CD25 and CD69 is presented in
histogram form (bold lines). Markers were placed so as not to include > 1%
of control Ig-stained cells (plain lines). Histograms are representative and
the mean percentages 6 SD from three mice in each group are shown.
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The effect of treatment with anti-CTLA-4 MoAb at primary
sensitization is long lasting To examine how long the effect
of anti-CTLA-4 MoAb treatment lasts in vivo, mice were primarily
sensitized with FITC after either control Ig or anti-CTLA-4
treatment. After 5 wk (on day 35), which might be a suf®cient time
for clearance of the injected MoAb and quiescence of the induced
activated T cells, either DNFB or FITC was applied as a secondary
Ag and CH reaction against each secondary Ag was measured. The
mice treated with anti-CTLA-4 MoAb at the primary sensitization
exhibited signi®cantly enhanced ear swelling to FITC, whereas no
signi®cant difference was observed by DNFB challenge (Fig 5).
DISCUSSION
We here demonstrated that the administration of anti-CTLA-4
MoAb at primary sensitization, but not at challenge, enhanced both
Th1- and Th2-mediated CH reactions. Accumulating reports
demonstrated that the in vivo administration of intact anti-CTLA-4
MoAb or anti-CTLA-4 Fab produces an antagonistic activity in
various T-cell-mediated immune responses (Kearney et al, 1995;
Karandikar et al, 1996; Perrin et al, 1996; McCoy et al, 1997;
Sakurai et al, 2000). Consistent with these results, administration of
anti-CTLA-4 and Fab of anti-CTLA-4 MoAb showed an
antagonistic function in this CH model. Our extensive kinetic
studies for CTLA-4 expression in cell surface and cytoplasmic
protein and mRNA levels showed a low but substantial expression
of CTLA-4 in intact LN T cells and a transcriptional activation after
Ag application. A low level of CTLA-4 expression may be enough
to be functional, as CTLA-4 possesses high af®nity to its ligands.
Despite the inducible expression of CTLA-4, the treatment with
anti-CTLA-4 MoAb at challenge did not affect CH responses. This
may suggest less dependence of T cell costimulation in the effector
phase of CH responses as described previously (Nuriya et al, 1996).
In this study, we used two different allergens: DNFB and FITC.
Tang et al (1996) reported that DNFB-induced CH was Th1-
predominant, whereas FITC-induced CH was Th2-predominant,
based on the analysis of draining LN cells producing interferon-g
and interleukin-4. The fact that blockade of CTLA-4 at
sensitization enhanced both types of CH reactions suggests that
CTLA-4 regulates differentiation to both Th1 and Th2 cells.
Previous reports demonstrated that both Th1 and Th2 clones or
lines express CTLA-4 with similar kinetics and both Th1 and Th2
cytokine production was inhibited by CTLA-4 blockade (Alegre et
al, 1998; Chen et al, 1998). On the other hand, several reports
suggested polarization of naive T cells toward Th2 cells by CTLA-4
blockade in vitro (Chen et al, 1998; Blazer et al, 1999; Ratts et al,
1999; Kato and Nariuchi, 2000). In vivo blockade of CTLA-4,
however, has clearly been shown to accelerate Th2-mediated
immune responses (McCoy et al, 1997; Murphy et al, 1998) as well
as Th1-mediated immune responses (Kearney et al, 1995;
Karandikar et al, 1996; Perrin et al, 1996; Luhder et al, 1998;
Blazer et al, 1999). Two reports demonstrated that engagement of
CTLA-4 induced transforming growth factor b production, which
contributed to the downregulation of T cell activation or
polarization to Th1 cells (Chen et al, 1998; Kato and Nariuchi,
2000). Recently, the involvement of CTLA-4 function in
CD25+CD4+ regulatory cells has been reported (Read et al,
2000; Takahashi et al, 2000). Blockade of CTLA-4 expressed on
regulatory T cells suf®ces to break natural self-tolerance and elicit
pathologic autoimmunity. Glass et al (1990) showed the induction
of not only memory T cells but also suppressor T cells during
sensitization in hapten-induced CH. In addition, a recent report
suggested the contribution of CTLA-4+ T cells producing
interleukin-10 in ultraviolet-B-induced tolerance (Schwarz et al,
2000). Therefore, it is possible that the blockade of CTLA-4 may
result in abrogation of the function of regulatory T cells or
regulatory cytokines in the CH reaction. Further studies are
required to clarify this issue.
Our results clearly demonstrated that blockade of CTLA-4
induced hapten-speci®c T cell activation and this effect was long-
lasting after the clearance of the injected MoAb and the quiescence
of activated T cells (Fig 5). These results suggest that blockade of
CTLA-4 at the primary Ag sensitization may decrease the threshold
of stimulation at T cell priming and increase the number of Ag-
reactive T cells. These may result in enhancing the number of
memory T cells in the regional LN. The Ag-primed memory T
cells could rapidly respond against the secondary challenged same
Ag. Therefore, the anti-CTLA-4 MoAb treated mice could exhibit
a high sensitivity against the primarily applied Ag alone. In this
experimental setting, we could not distinguish the ligands con-
tributing to CTLA-4 function. We previously demonstrated that
Ag-captured migratory Langerhans cells preferentially express
CD86 but not CD80 (Nuriya et al, 1996). Therefore, the treatment
with anti-CTLA-4 MoAb may preferentially inhibit the inter-
actions with CD86 on migrated Langerhans cells and CTLA-4 on
T cells in regional LN. It should be noted that blockade of CTLA-4
induced applied-hapten-independent T cell activation. We ob-
served a minimum but substantial enhancement in total LN cell
number and spontaneous proliferative responses by anti-CTLA-4
MoAb treatment without sensitization (Figs 2A, 4B). Similar
observations were reported by Walunas and Bluestone (1998).
These responses may be mediated by sustained memory T cell
activation against endogenous and/or environmental Ags encoun-
tered during the treatment.
In this study, we demonstrated that blockade of CTLA-4 at
sensitization, but not at challenge, signi®cantly enhanced Th1- and
Th2-mediated CH reactions. CTLA-4 was faintly expressed on
regional LN T cells even in intact mice and was enhanced after
sensitization. Blockade of CTLA-4 at sensitization augmented the
number of Ag-reactive T cells in regional LN and induced long-
lasting higher proliferative responses against speci®c haptens. Our
results suggest that CTLA-4 expressed on regional LN T cells may
play an important regulatory role in the generation of allergen-
speci®c T cells, which interact with skin-associated antigen-
presenting cells in allergic contact dermatitis.
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